Erik Burton
Neurology · Shreveport, LANPI 1730381179
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,938 of the $154,499 with a category attached, or 67.3%. Novartis accounts for 71.5% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2019 at $117,383 and has fallen 97.9% since, to $2,518 in 2025. Among neurology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,101 payments — averaging $140.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$110K
- AstraZeneca$17K
- EMD Serono, Inc.$9K
- Sanofi$7K
- AbbVie$2K
- Amgen$2K
- plus $7K from 37 others
Across 7 payments — averaging $5345.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$37K
What the payments were for
- Consulting fees$14,1789%
- Speaking & faculty fees$103,93867%
- Travel & lodging$20,16713%
- Food & beverage$16,21610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$154,499 in reported general payments places this provider in the 95th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 231 | $2,124,400 |
| MayzentSiponimod | 62 | $584,645 |
| BetaseronInterferon Beta-1b | 18 | $167,912 |
| Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-50 | 13 | $152,583 |
| TysabriNatalizumab | 18 | $147,977 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 15 | $119,753 |
| Dalfampridine ErDalfampridine | 220 | $90,878 |
| Nurtec OdtRimegepant Sulfate | 60 | $88,700 |
| GlatopaGlatiramer Acetate | 26 | $68,171 |
| IngrezzaValbenazine Tosylate | 11 | $41,579 |
| MyrbetriqMirabegron | 72 | $28,895 |
| Emgality PenGalcanezumab-Gnlm | 23 | $21,268 |
| NuedextaDextromethorphan Hbr/Quinidine | 18 | $14,100 |
| LinzessLinaclotide | 21 | $10,965 |
| ReyvowLasmiditan Succinate | 12 | $8,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMayzent | $110,434 | $584,64562 claims |
| BiogenTysabri | $780 | $147,97718 claims |
| PfizerNurtec Odt | $680 | $88,70060 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $56 | $41,57911 claims |
| AbbVieLinzess | $2,307 | $10,96521 claims |
| Lilly USA, LLCReyvow | $118 | $8,99612 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $31 | $1,35219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 neurology providers in Louisiana.
Other neurology in Shreveport
- Meghan HarrisShreveport$553K
- Ernest LittleShreveport$52K
- Chaitanya AmrutkarShreveport$17K
- Debra DavisShreveport$16K
- Jenny GuerreShreveport$15K
- Gurleen SikandShreveport$14K
- Kevin CallerameBaton Rouge$420K
- Gerald CaleganBaton Rouge$400K
- Maria Carmen WilsonCovington$295K
- John EnglandNew Orleans$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.